You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Connecting the Dots in Unresectable HCC: Harnessing New Data to Optimize First-Line Therapy for Individual Patients

  • Authors: Robin (Katie) Kelley, MD; Peter R. Galle, MD, PhD
  • CME / ABIM MOC Released: 7/20/2023
  • Valid for credit through: 7/20/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.25 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for medical and surgical oncologists, gastroenterologists, hepatologists, interventional radiologists, and other clinicians who treat patients with HCC.

The goal of this activity is for learners to be better able to apply new clinically relevant data to the care of patients with unresectable HCC in order to increase multidisciplinary care and improve outcomes.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • New data from clinical trials evaluating treatment for patients with unresectable HCC
  • Have greater competence related to
    • Incorporating new clinically relevant data from a major oncology medical meeting into the care of patients with unresectable HCC


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Robin (Katie) Kelley, MD

    Professor of Clinical Medicine
    Department of Medicine (Hematology/Oncology)
    University of California, San Francisco
    San Francisco, California, United States

    Disclosures

    Robin (Katie) Kelley, MD, has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca Pharmaceuticals LP; Compass Therapeutics; Exelixis, Inc.; J Pharma; Kinnate; Merck; Tyra Biosciences
    Research funding from: Agios Pharmaceuticals; AstraZeneca Pharmaceuticals LP; Bayer; Bristol Myers Squibb Company; EMD Serono; Genentech; Lilly; Loxo Oncology; Merck; Novartis; Partner Therapeutics; QED; Relay Therapeutics; SERVIER; Surface Oncology; Taiho Pharmaceutical Co., Ltd.

  • Peter R. Galle, MD, PhD

    Professor and Chairman
    First Department of Internal Medicine
    University Medical Cancer Mainz
    Mainz, Germany

    Disclosures

    Peter R. Galle, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: Adaptimmune; AstraZeneca Pharmaceuticals LP; Bayer; Boston Scientific; Bristol Myers Squibb Company; Eisai Inc.; Guerbet; Ipsen; Lilly; Merck Sharp & Dohme, Corp.; Roche; Sirtex
    Speaker or member of speakers bureau for: Adaptimmune; Bayer; Ipsen; Lilly; Roche; Sirtex
    Research funding from: Bayer; Roche

Editor

  • Davecia R. Cameron, MS

    Medical Education Director, Medscape, LLC

    Disclosures

    Davecia R. Cameron, MS, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Connecting the Dots in Unresectable HCC: Harnessing New Data to Optimize First-Line Therapy for Individual Patients

Authors: Robin (Katie) Kelley, MD; Peter R. Galle, MD, PhDFaculty and Disclosures

CME / ABIM MOC Released: 7/20/2023

Valid for credit through: 7/20/2024, 11:59 PM EST

processing....

Contents of This CME Activity

To start this activity, please assess your clinical knowledge by completing the brief survey at the bottom. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Diving Into the New Data

Dr Katie Kelley discusses the latest data for unresectable, advanced HCC.
Robin (Katie) Kelley, MD

Clinical Impacts of the New Data

Dr Peter Galle reviews the impact that new data will have on the survival outcomes of patients with unresectable, advanced HCC.
Peter R. Galle, MD, PhD
 

Learning Feedback Questions

Please answer the questions below to self-assess your knowledge. Answering these questions again after the activity will allow you to see what you learned.

  • Print